MSB 4.69% $1.45 mesoblast limited

Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-182

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,215 Posts.
    lightbulb Created with Sketch. 951

    Maxim Group Stick to Their Buy Rating for Mesoblast Ltd

    investing-new.pngFeb 09, 2021 04:10AM ET



    Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast (NASDAQ:MESO) Ltd on Thursday, setting a price target of $16, which is approximately 55.49% above the present share price of $10.29.

    McCarthy expects Mesoblast Ltd to post earnings per share (EPS) of $0.00 for the first quarter of 2021.

    The current consensus among 5 TipRanks analysts is for a Hold rating of shares in Mesoblast, with an average price target of $12.7.
    The analysts price targets range from a high of $18 to a low of $6.

    In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.31 million and a net profit of -$35.56 million. The company's market cap is $1.21 billion.

    According to TipRanks.com, Maxim Group analyst Jason McCarthy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 78.0% and a 73.50% success rate.

    Meh, if they're shorting right now, they really might get burnt:

    https://www.investing.com/news/maxim-group-stick-to-their-buy-rating-for-mesoblast-ltd-2413142




 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.